Ivermectin resistance mechanisms in ectoparasites: a scoping review
- PMID: 38787430
- PMCID: PMC11126493
- DOI: 10.1007/s00436-024-08223-z
Ivermectin resistance mechanisms in ectoparasites: a scoping review
Abstract
Ivermectin mass drug administration has been used for decades to target human and veterinary ectoparasites, and is currently being considered for use against malaria vectors. Although there have been few reports of resistance to date in human ectoparasites, we must anticipate the development of resistance in mosquitoes in the future. Hence, through this review, we mapped the existing evidence on ivermectin resistance mechanisms in human ectoparasites. A search was conducted on the 8th November 2023 through databases, PubMed, Web of Science, and Google Scholar, using terms related to ivermectin, human and veterinary ectoparasites, and resistance. Abstracts (5893) were screened by JFA and CK. Data on the study organism, the type of resistance, the analysis methods, and, where applicable, the gene loci of interest were extracted from the studies. Details of the methodology and results of each study were summarised narratively and in a table. Eighteen studies were identified describing ivermectin resistance in ectoparasites. Two studies described target site resistance; and 16 studies reported metabolic resistance and/or changes in efflux pump expression. The studies investigated genetic mutations in resistant organisms, detoxification, and efflux pump expression in resistant versus susceptible organisms, and the effect of synergists on mortality or detoxification enzyme/efflux pump transcription. To date, very few studies have been conducted examining the mechanisms of ivermectin resistance in ectoparasites, with only two on Anopheles spp. Of the existing studies, most examined detoxification and efflux pump gene expression, and only two studies in lice investigated target-site resistance. Further research in this field should be encouraged, to allow for close monitoring in ivermectin MDA programmes, and the development of resistance mitigation strategies.
Keywords: Ectoparasites; Endectocide; Insecticide resistance; Ivermectin; Mosquitoes.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Potential metabolic resistance mechanisms to ivermectin in Anopheles gambiae: a synergist bioassay study.Parasit Vectors. 2021 Mar 20;14(1):172. doi: 10.1186/s13071-021-04675-9. Parasit Vectors. 2021. PMID: 33743783 Free PMC article.
-
Pharmacotherapy of ectoparasitic infections.Drugs. 2001;61(8):1067-88. doi: 10.2165/00003495-200161080-00004. Drugs. 2001. PMID: 11465870 Review.
-
Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes.Malar J. 2023 Jun 24;22(1):194. doi: 10.1186/s12936-023-04624-0. Malar J. 2023. PMID: 37355605 Free PMC article.
-
Ivermectin as a novel malaria control tool: Getting ahead of the resistance curse.Acta Trop. 2023 Sep;245:106973. doi: 10.1016/j.actatropica.2023.106973. Epub 2023 Jun 22. Acta Trop. 2023. PMID: 37352998
-
Ectoparasites of medical and veterinary importance: drug resistance and the need for alternative control methods.J Pharm Pharmacol. 2015 Mar;67(3):351-63. doi: 10.1111/jphp.12368. Epub 2015 Feb 3. J Pharm Pharmacol. 2015. PMID: 25644683 Review.
Cited by
-
A proof-of-concept experimental-theoretical model to predict pesticide resistance evolution.Heredity (Edinb). 2025 Jul 23. doi: 10.1038/s41437-025-00781-x. Online ahead of print. Heredity (Edinb). 2025. PMID: 40702313
-
Comparative susceptibility of wild and laboratory-reared Aedes and Anopheles larvae to ivermectin.Malar J. 2025 Jul 8;24(1):222. doi: 10.1186/s12936-025-05470-y. Malar J. 2025. PMID: 40629371 Free PMC article.
References
-
- Álvarez-Sánchez ME, Ruiz-May E, Aguilar-Tipacamú G, Elizalde-Contreras JM, Bojórquez-Velázquez E, Zamora-Briseño JA, et al. The ovaries of Ivermectin-resistant Rhipicephalus microplus strains display proteomic adaptations involving the induction of xenobiotic detoxification and structural remodeling mechanisms. J Proteomics. 2023;280:1–12. doi: 10.1016/j.jprot.2023.104892. - DOI - PubMed
-
- Atif M, Smith JJ, Estrada-Mondragon A, Xiao X, Salim AA, Capon RJ, et al. (2019) GluClR-mediated inhibitory postsynaptic currents reveal targets for Ivermectin and potential mechanisms of Ivermectin resistance. PLOS Pathog [Internet]. [cited 2022 Mar 24];15(1):e1007570. Available from: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.... - PMC - PubMed
-
- Awadzi K, Attah SK, Addy ET, Opoku NO, Quartey BT, Lazdins-Helds JK, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol. 2004;98(4):359–370. doi: 10.1179/000349804225003442. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous